Action of prostanoids on the emetic reflex of Suncus murinus (the house musk shrew).
Several prostanoids were investigated for a potential to induce emesis in Suncus murinus. The TP receptor agonist 11alpha,9alpha-epoxymethano-15S-hydroxyprosta-5Z,13E-dienoic acid (U46619) induced emesis at doses as low as 3 microg/kg, i.p. but the DP receptor agonist 5-(6-Carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl) hydantoin (BW245C) was approximately 1000 times less potent. The emetic action of U46619 (300 microg/kg, i.p.) was antagonized significantly by the TP receptor antagonist, vapiprost (P<0.05). EP (prostaglandin E(2), 17-phenyl-omega-trinor prostaglandin E(2), misoprostol and sulprostone), FP (prostaglandin F(2alpha) and fluprostenol) and IP (iloprost and cicaprost) receptor agonists failed to induce consistent emesis at doses up to 300-1000 microg/kg, i.p. Fluprostenol reduced nicotine (5 mg/kg, s.c.)-but not copper sulphate (120 mg/kg, intragastric)-induced emesis; the other inconsistently emetic prostanoids were inactive to modify drug-induced emesis. The results indicate an involvement of TP and possibly DP and FP receptors in the emetic reflex of S. murinus.
Kan
Kelvin K W
KK
Department of Pharmacology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, China.
Jones
Robert L
RL
Ngan
Man P
MP
Rudd
John A
JA
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors; D000818:Animals; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D019327:Copper Sulfate / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D006827:Hydantoins / Q000008:administration & dosage; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007441:Intubation, Gastrointestinal; D008297:Male; D009325:Nausea / Q000503:physiopathology; D009538:Nicotine / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors; D011453:Prostaglandins / Q000008:administration & dosage / Q000009:adverse effects*; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D011930:Reaction Time; D017482:Receptors, Thromboxane / Q000187:drug effects / Q000502:physiology; D012788:Shrews / Q000502:physiology*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*
D001713:Biphenyl Compounds; D006538:Heptanoic Acids; D006827:Hydantoins; D011453:Prostaglandins; D011461:Prostaglandins F, Synthetic; D017482:Receptors, Thromboxane; C006326:fluprostenol; D009538:Nicotine; C030669:BW 245C; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; C060013:vapiprost; D019327:Copper Sulfate